Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, is pleased to announce it has restarted patient recruitment for its Phase 2a clinical trial in AD which was suspended due to COVID-19 in March 2020, and initiated recruitment for its new Phase 2a clinical trial in AD and PD.
August 20, 2020
· 3 min read
